Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Highly Accessed Research article

Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury

Marc Schoeler1, Philip D Loetscher1, Rolf Rossaint1, Astrid V Fahlenkamp1, Georg Eberhardt1, Steffen Rex13, Joachim Weis2 and Mark Coburn1*

Author Affiliations

1 Department of Anesthesiology, University Hospital of the RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

2 Institute of Neuropathology, University Hospital of the RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

3 Department of Anesthesiology, University Hospital of the KU Leuven, Herestraat 49, 3000 Leuven, Belgium

For all author emails, please log on.

BMC Neurology 2012, 12:20  doi:10.1186/1471-2377-12-20

Published: 11 April 2012

Abstract

Background

The α2-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro model for traumatic brain injury.

Methods

Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway inhibitors were examined.

Results

Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum effect at a dosage of 1 μM. This effect was partially reversed by the simultaneous administration of the ERK inhibitor PD98059.

Conclusion

In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that activation of ERK might be involved in mediating this effect.

Keywords:
Neuroprotection; Traumatic brain injury; Dexmedetomidine